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Abstract 
CRITICAL ISCHEMIA IN THE DIABETIC: DIAGNOSIS AND TREATMENT 
Roncon-Albuquerque, R.; Fragoeiro, A. 
Objectives: Critical ischemia plays a prominent role in the formation of diabetic foot 
ulcers. Despite its significance, diagnosis is difficult in diabetic patients, delaying 
treatment. The most feared consequence is amputation and many attempts have been 
made over the years to avoid this outcome. The aim of this review is to discuss the 
current methods of diagnosis and treatment of ischemic and neuroischemic diabetic foot 
ulcers. 
Methods: A selective search on PubMed  was  conducted  with  the  term  “diabetic foot”.  
Results were limited to publications within the last 10 years, in English or Portuguese, 
with available free full text and relative to humans. The search yielded 457 results and 
subsequent elimination was based on relevance of the information to this review. 
Results: Although the prevalence of diabetes mellitus is increasing worldwide, 
improvement in diabetic foot ulcer outcomes has been made thanks to a protocol-driven 
multidisciplinary approach. A wide range of revascularization techniques are available 
and intensive research has been made to procure options for patients who are not 
candidates. 
Conclusion: Treatment of diabetic foot ulcers should be multifactorial and the selection 
of therapy to   improve   perfusion   should   be   based   on   the   patient’s   general   health  
condition, comorbidities, symptoms and clinical findings, arterial anatomy and conduit 
availability. Noninvasive treatment is a promising option for patients ineligible for 
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revascularization, but requires further trials to prove efficacy and guide potential 
integration in treatment. 
 
Resumo 
ISQUEMIA CRÍTICA NO DIABÉTICO: DIAGNÓSTICO E TRATAMENTO 
Roncon-Albuquerque, R.; Fragoeiro, A. 
Objetivos: A isquemia crítica tem um papel proeminente na formação de úlceras do pé 
diabético. Apesar da sua importância, o diagnóstico é difícil, atrasando o tratamento. A 
consequência mais temida é a amputação e várias tentativas têm sido feitas para evitar 
este desfecho. O objetivo desta revisão é discutir os atuais métodos de diagnóstico e 
tratamento de úlceras isquémicas e neuro-isquémicas no diabético. 
Métodos: Uma pesquisa seletiva na PubMed foi realizada com  o  termo  “pé  diabético”.  
Os resultados foram limitados a publicações nos últimos 10 anos, em inglês ou 
português, com texto integral disponível gratuitamente e relativo a humanos. Da 
pesquisa obtiveram-se 457 artigos e a subsequente eliminação teve base na relevância 
da informação para esta revisão. 
Resultados: Apesar da prevalência da diabetes mellitus estar a aumentar mundialmente, 
uma melhoria no prognóstico tem sido obtida graças a uma abordagem multidisciplinar 
dirigida por protocolos. Uma grande variedade de técnicas de revascularização estão 
disponíveis e pesquisa intensiva tem sido feita para procurar opções para doentes que 
não sejam candidatos. 
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Conclusão: O tratamento de úlceras do pé diabético deve ser multifatorial e a escolha 
da terapêutica para melhorar a perfusão deve ser baseada no estado geral do doente, co-
morbilidades, sintomas e achados clínicos, anatomia arterial e disponibilidade de 
conduto. Tratamento não invasivo é uma opção promissora para doentes inelegíveis 
para revascularização, mas requer mais estudos para comprovar a eficácia e guiar a 
potencial integração no tratamento. 
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List of acronyms and abbreviations 
ABI – ankle-brachial index 
BASIL – bypass versus angioplasty in severe ischaemia of the leg (trial) 
CLI – critical limb ischemia 
DFU – diabetic foot ulcer(s) 
FGF – fibroblast growth factor 
HbA1c – hemoglobin A1c 
HGF – hepatocyte growth factor 
NPWT – negative pressure wound therapy 
PAD – peripheral arterial disease 
PTA – percutaneous transluminal angioplasty 
TcPO2 – transcutaneous oxygen pressure 
VEGF – vascular endothelial cell growth factor 
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Introduction 
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis that leads 
to arterial stenosis and occlusions in the major vessels supplying the lower limbs. The 
most common symptom of PAD is intermittent claudication, characterized by 
reproducible muscular leg pain on exercise that is relieved by short rest. In more severe 
cases there may be chronic ischemic rest pain, which usually indicates critical limb 
ischemia (CLI) [1]. PAD is 2-4 times more common in patients with diabetes than in 
those without [2] and in diabetic patients with foot ulcers the prevalence of PAD can 
reach up to 50% [3]. The most feared complication of PAD is amputation and diabetic 
foot complications remain the main cause of non-traumatic amputation in most western 
countries [4]. The diabetic foot is a challenging personal, medical, social and economic 
problem that is seen worldwide [5]. An effort has been made over the years to reduce 
diabetic foot complications and it is believed that a strategy including prevention, 
patient and staff education, multidisciplinary treatment of ulcers and close monitoring 
can reduce amputation rates by 49-85% [6]. The aim of this review is to discuss the 
current methods of diagnosis and treatment of ischemic and neuroischemic diabetic foot 
ulcers (DFU). 
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Material and Methods 
A selective search on PubMed was conducted with   the   term   “diabetic   foot”.  
Results were limited to publications within the last 10 years, in English or Portuguese, 
with available free full text and relative to humans. The search yielded 457 articles. 
Subsequent inclusion or elimination of articles was based on the information 
contained in the titles and abstracts. Articles which were not relevant to the 
pathophysiology, diagnosis and treatment of DFU were excluded. The type of 
publication was also taken into consideration, and letters, news and editorials were 
excluded. 
Other articles were acquired because of their reference in reviews obtained in 
the first search. Also, a few smaller searches were performed to gain information on 
certain subjects such as therapeutic angiogenesis and drug-eluting stents, which are 
somewhat recent topics in investigation and possess more trials in a non-diabetic 
population, therefore not appearing in the first search. 
To obtain recent statistics of diabetes mellitus, the International Diabetes 
Federation site was also consulted. 
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PAD and critical ischemia 
PAD is a manifestation of atherosclerosis that leads to arterial stenosis and 
occlusions in the major vessels supplying the lower limbs [1]. CLI represents the end 
stage of PAD, referring to a state of arterial insufficiency that reduces distal perfusion 
pressure to such an extent that nutritive blood flow and microcirculation to tissues are 
severely reduced and tissue viability is jeopardized [7]. Patients typically present with 
chronic ischemic rest pain (Rutherford categories 4 to 6) and/or ischemic skin lesions 
such  as  ulceration  or  gangrene  (Fontaine’s  stages  III  and  IV).  It should be remembered 
that CLI implies chronicity, requiring the presence of symptoms for over 2 weeks, 
distinguishing it from acute limb ischemia. The diagnosis of CLI should be confirmed 
by studies such as ankle-brachial index (ABI), toe systolic pressure or transcutaneous 
oxygen pressure (TcPO2) [1], to be discussed later in this review. 
 
Diabetes mellitus and diabetic foot 
Diabetes mellitus is a serious healthcare problem, with an increasing 
prevalence worldwide. According to the International Diabetes Federation estimates of 
2012, over 371 million people have diabetes [8]. The  term  “diabetic  foot”  encompasses  
any foot lesion occurring as a result of diabetes and its complications [6] and the lifetime 
risk of a patient with diabetes developing a foot ulcer has been estimated to be as high 
as 25% [4]. The condition constitutes a major disabling complication, with potentially 
limb-threatening consequences. It has been claimed that every 30 seconds a lower limb 
is amputated due to diabetes [9] and that over 85% of amputations are preceded by a foot 
ulcer [5]. The single greatest risk factor for foot ulceration is a past history of either 
ulceration or amputation [10]. 
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Ischemia, neuropathy and infection are the three pathological components 
involved in the etiology of DFU, frequently occurring together [11]. Neuropathy and 
ischemia are usually the initiating factors, bearing a different weight in different 
patients. Infection is rarely the direct cause of an ulcer, but is strongly related to the 
probability of amputation, especially in combination with PAD [12]. The distinction 
between purely neuropathic, purely ischemic or neuroischemic ulcers is essential, as it 
will guide further therapy. Up to 50% of DFU are considered to be of neuroischemic 
origin and one-third of the patients with a foot ulcer have both signs of PAD and 
infection [1, 13]. 
It is important to recognize that the DFU is a sign of multiorgan disease. 
Patients frequently possess multiple comorbidities such as cardiovascular disease and 
end stage renal disease [14] that may be the result of the micro and macrovascular 
disturbances caused by hyperglycemia or integrate the metabolic syndrome common in 
diabetics [15, 16]. 
 
Diabetes mellitus and PAD 
Both macrovascular disease and microvascular dysfunction impair perfusion in 
the diabetic foot, yet the most important cause of vascular impairment is PAD [17]. PAD 
is 2-4 times more common in patients with diabetes than in those without [2], but the true 
prevalence of PAD in the diabetic population is difficult to determine. Studies point to a 
PAD prevalence of up to 50% in diabetic patients with foot ulcers [3]. Although the 
major risk factors (age, smoking, hypertension, dyslipidemia, etc) are the same for 
diabetic and non-diabetic PAD, diabetic PAD occurs at a younger age, with a roughly 
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even distribution amongst men and women and characteristically advances more rapidly 
[17]. 
PAD risk is associated with duration and control of diabetes. Poor glucose 
control accelerates the manifestation of PAD and for every 1% increase in hemoglobin 
A1c (HbA1c) there is a corresponding increase of 25-60% in the relative risk of PAD 
[18]. There is also evidence suggesting that insulin resistance plays a key role in a 
clustering of cardiometabolic risk factors which include hyperglycemia, dyslipidemia, 
hypertension and obesity. Insulin resistance is a risk factor for PAD even in individuals 
without diabetes, raising the risk approximately 40 to 50% [19]. 
The pattern of arterial involvement differs in comparison to that of non-
diabetics. Atherosclerosis is usually distally located, with a predilection for the 
infrapopliteal vessels. Proximal segments may also be involved, especially in diabetic 
smokers. The atherosclerotic process is more diffuse and there is poor collateral 
circulation [17]. 
The clinical presentation of PAD in the diabetic patient is frequently 
masqueraded due to concomitant peripheral neuropathy. The presence of calcification of 
the intimal plaque and media (Mönckeberg’s media calcinosis), a condition frequently 
associated with diabetic PAD, may further hinder the diagnosis [17]. In all patients with 
diabetes and a foot ulcer, the presence of PAD must be excluded [3, 9]. 
A fact to be well kept in mind when managing a diabetic patient is that the 
presence of PAD indicates generalized atherosclerosis, including a coronary or 
cerebrovascular distribution that may be asymptomatic [17]. 
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Patients with a history of DFU alone already have high mortality rates, mainly 
due to cardiovascular events but also due to other causes such as cancer [20]. However, 
PAD, especially CLI, significantly increases the mortality risk further [21]. 
 
Diagnosis 
Until PAD is excluded, vascular status of the lower extremities should always 
be evaluated in a patient with a DFU [3]. The clinician should begin by taking a thorough 
history, with identification of common risk factors, family history of diabetes, personal 
history of ulceration or other chronic wounds, venous disease or previous vascular 
evaluation [17]. The presence of PAD symptoms must be questioned, such as intermittent 
claudication or rest pain [3]. However, less than 25% of diabetics with PAD report these 
symptoms, which may delay the diagnosis of ischemia [6]. 
Physical examination must include inspection of both legs and feet and 
palpation of peripheral pulses.  Vascular insufficiency is suggested by absence of hair, 
dry, cool or fissured skin, dystrophic nails, skin pallor and dependent erythema. Signs of 
venous disease should also be assessed, such as varicose veins, brawny induration, or 
scarring. Any foot deformity, callus or scarring must be investigated and the interdigital 
spaces must be inspected for possible fissures, ulceration or infection. Neuropathy 
should be assessed by sensory, proprioceptive and vibratory testing. Pulses of the lower 
limb (femoral, popliteal, posterior tibial and dorsalis pedis arteries) are to be palpated 
bilaterally [17]. When both pedal pulses are absent, PAD is likely. A hand-held Doppler 
examination should be performed to assist in the vascular examination. Absent or 
monophasic Doppler signals from one or both feet suggest PAD [3]. 
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The use of rigid non-invasive methods is mostly based on the hemodynamic 
changes in the macrovascular arterial tree. The criteria applicable to non-diabetic lower 
limbs are not reliable to predict the healing of diabetic foot lesions [1]. ABI is obtained 
by dividing the ankle systolic pressure by the brachial systolic pressure, derived from 
Doppler examination. ABI may be falsely elevated due to media calcinosis, and 
therefore can be trusted when low but not when high [17]. An ABI < 0.6 indicates 
significant ischemia in respect to wound healing potential, whereas an ABI > 0.6 has 
little predictive value and, therefore, toe pressure and/or transcutaneous oxygen pressure 
(TcPO2) should be measured [3]. Toe pressure may give more reliable information on the 
level of distal flow capacity but, as reported in one study, it could not be measured in 
16% of cases due to a previous amputation or gangrene of the big toe [21]. When it 
comes to evaluating arterial circulation of the lower limbs, measurement of toe blood 
pressure is superior to the calculation of ABI as media calcinosis is almost absent in the 
digital arteries [7]. To investigate local microcirculation and tissue viability, TcPO2 of 
the forefoot should be measured, as it reflects local arterial blood flow and skin 
oxygenation [7]. DFU will often heal if toe pressure is >55 mmHg and TcPO2 >50 
mmHg. Healing is usually severely impaired when toe pressure is <30 mmHg and 
TcPO2 <30 mmHg [3]. 
Even if initial diagnostics have suggested only questionable or mild disease, 
when a DFU has not healed with proper treatment in 6 weeks perfusion should be 
reassessed. Duplex ultrasound or angiography are the diagnostic tests to be considered 
[3].  Duplex ultrasound can directly visualize most vessels, but is most often used for 
post-bypass graft or angioplasty and stent procedure surveillance. Contrast angiography 
can be executed with magnetic resonance angiography, computed tomographic 
angiography or with conventional digital subtraction arteriography. Special precautions 
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must be taken due to the increased risk of contrast-induced nephrotoxicity in diabetics. 
These patients require hydration in preparation and monitoring of renal function after 
the procedure [17]. 
 
Treatment 
The main goal when treating CLI and DFU is preservation of the limb. 
Ischemia is primarily responsible for 90% of amputations in DFU patients [22]. When 
left untreated, the poor arterial perfusion in CLI may lead to the need for amputation [23] 
and potentially fatal complications from the progression of gangrene and the 
development of sepsis [24]. 
Understanding the underlying pathophysiology of DFU is essential, as it guides 
in the selection of treatment options. Regardless of the type of ulcer, a multifactorial 
approach is necessary and provides the best results. The greatest challenge is in healing 
ischemic or neuroischemic ulcers, due to the low distal perfusion pressure and 
microvascular dysfunction. Exclusively neuropathic ulcers have a good prognosis as 
long as adequate and timely treatment is given [23]. 
The treatment of purely neuropathic and infected foot ulcers is beyond the 
scope of this review. Focus will be on the improvement of perfusion, by medical, 
endovascular or surgical means. 
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Medical management 
Therapeutic goals in diabetic patients with foot ulcers include pain control, 
biomechanical off-loading,  improvement of perfusion, wound bed  dressings and 
topical treatment, frequent debridement, correction of foot deformities and reduction of 
edema [25]. Prevention and treatment of infection is also a key component of treatment, 
for infection dramatically increases the risk of amputation [12]. When ischemia and 
infection are presented together, “time   is   tissue”  and urgent treatment is necessary [3]. 
Be mindful of the fact that reconstruction of the blood supply to the lower limb 
increases   the   body’s   ability   to   fight   infections.   By   satisfying   nutrient demand, 
accelerating local tissue metabolism and promoting the recovery of diseased nerves at 
the distal end of the limb, better control of local infection and faster healing of foot 
ulcers is achieved [15]. 
As previously discussed, poor metabolic control accelerates the development of 
PAD [18]. It is thus recommended that medical treatment be aimed at achieving HbA1c 
levels of <7.0% in most adults [26]. Patients with DFU also possess elevated 
cardiovascular morbidity and mortality. Cardiovascular risk factor modification is 
indispensable, with treatment of hypertension and dyslipidemia, control of platelet 
aggregation and smoking cessation [3, 25].  
Negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy are 
two treatment modalities that are not established in routine management but that may 
prove useful in certain cases [6]. NPWT has been shown to promote wound healing by 
removing excess exudates, stimulating granulation tissue, providing a closed 
environment, reducing edema and increasing local blood flow. The prerequisite for ideal 
effect is adequate blood supply and can only be considered as complementary to other 
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treatments [27]. Hyperbaric oxygen treatment may reduce the risk of major amputation 
when given as an adjunct, but the type of patient most likely to benefit from this therapy 
is still to be determined [14]. 
 
Vascular interventions 
The crucial decision is whether revascularization is necessary in a particular 
patient with a particular lesion. Vascular surgery or angioplasty should be performed in 
any patient with PAD severe enough to impair wound healing in order to optimize 
peripheral arterial perfusion, improve ulcer healing and avoid amputation [3, 23]. The aim 
of revascularization is to restore blood flow to at least one infrapopliteal artery down to 
the foot, preferably the artery that supplies the anatomical region of the ulcer [3, 28]. Due 
to the difficulties in diagnosis, neuroischemic pattern of disease and microvascular 
dysfunction, the threshold for revascularization in patients with DFU should be lower 
[23]. Non-invasive evaluation is helpful in the decision, and revascularization is 
suggested when ABI < 0.6, toe pressures < 50 mmHg or TcPO2 < 30 mmHg [6]. 
Ultimately,   the  decision   to   intervene   is  made  according   to   the  patient’s  general  health 
status, comorbidities, symptoms and clinical findings [11, 29, 30]. Anatomical imaging of 
the entire lower limb circulation should be performed before vascular intervention to aid 
in the selection of a therapeutic strategy [3]. Atherosclerotic disease in diabetic patients 
frequently affects the infrapopliteal arteries, with sparing of the foot arteries. Diabetic 
smokers may also manifest iliac or femoral occlusions [31]. 
There are three revascularization techniques: open, endovascular, and hybrid [9, 
11, 25]. The choice between these methods depends on comorbidity, extension and 
severity of the arterial lesions and expertise of the center [25]. Although mortality and 
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amputation-free survival may be similar at a midterm follow-up [32], these results tilt in 
favor of bypass surgery on the long-term if the procedure is performed on medically fit 
patients using quality vein grafts [33, 34]. However, bypass surgery is associated with 
greater morbidity and mortality, and the possibility of prolonged ulcer healing, wound 
complications, limb swelling, perioperative cardiac complications, hospital readmission 
and graft failure leading to reoperation [24]. According to the results of the Bypass versus 
angioplasty in severe ischaemia of the leg (BASIL) trial, angioplasty should be 
considered first in patients with substantial comorbidities and life expectancy under 1 to 
2 years [32]. A propensity score analysis comparing surgical and endovascular 
techniques suggests otherwise, defending that outcomes do not differ except in respect 
to leg salvage (better in percutaneous transluminal angioplasty (PTA), 75.5% vs 68.0%, 
P = 0.042) and freedom from surgical revascularization (better in bypass, 78.8% vs 
85.2%, P = 0.17) and that infrapopliteal PTA should be considered a first-line strategy 
when both endovascular and bypass procedures are available for a certain patient with 
equal outcomes to be expected [35].  
Arterial bypass is an open surgery procedure and is indicated for long 
occlusions [25]. It must   be   individualized   according   to   the   patient’s   available   venous  
conduit and arterial anatomy [11]. Diabetic patients usually present with arterial 
occlusion in the superficial femoral or the popliteal artery and the distal arteries [36]. 
When the distal arteries are involved, distal bypass may be an option. This may prove 
challenging, as the distal outflow vessels in diabetics are often calcified. Inflow to the 
graft may be taken from the superficial femoral or popliteal artery if the proximal 
vessels are free of significant wall changes [25]. The best graft material in distal bypasses 
is autogenous vein. A retrospective study led by the Boston Deaconess Hospital Group 
reports that saphenous vein grafts were more efficacious than other conduits, presenting 
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superior patency rates. Autogenous vein also possesses a greater resistance to infection 
when compared with prosthetic grafts [37].  
Endovascular interventions, including PTA with or without stenting, are a less 
invasive alternative for revascularization. These techniques are suitable for focal, short-
segment iliac stenosis or occlusions, which occur in 10 to 20% of all diabetic patients 
[1]. However, with the development of new angioplasty procedures and different types of 
stents, endovascular treatment of infrapopliteal atherosclerotic occlusions and/or 
stenosis is becoming the gold-standard, especially in patients with CLI [38]. There have 
been many attempts to evaluate the role of bare-metal, metal-absorbable, carbofilm-
coated, or drug-eluting stent implantation in distal popliteal and infrapopliteal arteries, 
but these have yielded little information about the midterm and long-term outcomes [39]. 
The short lengths and the vulnerability to external compression and deformation if 
placed too distally are the main limitations of currently available bare or drug-eluting 
balloon-expandable stents. Longer length self-expanding thin-strut stents are available 
and more appropriate for the diffuse distribution of atherosclerosis commonly 
associated with CLI [38]. A retrospective study was conducted in Germany from 2005 to 
2008 to evaluate the effectiveness of nitinol stent placement in long infrapopliteal 
lesions in patients with CLI at high risk for crural bypass and with suboptimal 
angioplasty. The nitinol device is relatively long (120mm) and flexible, proving 
beneficial in long occlusions which are common in the crural arteries. The results 
support this option as a durable first-choice alternative treatment in these patients, with 
a success rate of 97.1%, short-term (10.4+/-7.3 months) primary patency rate of 91.1% 
and 75.5% primary patency rate at 24 months [39, 40]. Drug-eluting stents are being 
investigated as an option for reducing restenosis in the infrapopliteal arteries, a 
recurring problem in PTA, since bare metal stents are associated with significant 
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neointimal hyperplasia [38, 41]. Substances such as sirolimus (with anti-inflammatory and 
antiproliferative properties) and paclitaxel (antimitotic cytotoxic actions) have been 
used, showing encouraging results [38]. Sirolimus-eluting stents appear to be superior to 
paclitaxel-eluting stents in terms of primary patency (p<0.001) and repeat 
revascularizations (p = 0.014) [42]. The major concerns are the short length and elevated 
price of these devices, as the need for several stents to revascularize an infrapopliteal 
segment is not cost-effective [39]. Fracture of a drug-eluting stent in the tibioperoneal 
trunk following bifurcation stenting is also a considerable risk [43]. It should be stressed 
that in several randomized and non-randomized trials, higher primary and secondary 
patency rates were obtained in comparison to bare metal stents and PTA. No significant 
advantage has been demonstrated with regard to limb salvage and mortality rates. These 
results have yet to be tested in larger cohort studies and with greater follow-up periods 
[44]. 
Randomized controlled trials comparing endovascular and surgical 
revascularization in the treatment of impaired perfusion or critical ischemia in diabetics 
are not available to this date [29]. Bypass surgery and endovascular therapy should be 
considered complementary techniques for revascularization in diabetic patients with 
non-healing ulcers [45]. 
 
Noninvasive treatment of CLI 
Current treatment options for patients with DFU and CLI who are not 
candidates for revascularization or in which the procedure has been unsuccessful are 
scarce. These patients have a less favorable prognosis, with amputation possibly being 
the only viable choice. Recent research efforts have been made to find safe and effective 
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noninvasive approaches to improve peripheral arterial perfusion. Prostaglandin therapy 
and urokinase administration were first studied over a decade ago, but larger and more 
recent randomized and controlled trials are needed to better assess the value and 
efficacy of these treatments in this subset of patients. Stimulation of angiogenesis is a 
novel technique being currently explored in various studies [46]. 
Prostanoids prevent platelet aggregation and leukocyte activation and protect 
the vascular endothelium. Though treatment with local infusion of prostaglandin E1 is 
still controversial, the majority of current guidelines recommend this procedure in 
patients with DFU and CLI without revascularization options. The Inter-Society 
Consensus for the Management of PAD (TASC II) however, does not [1]. Short-term 
studies have not shown clear results, but most long-term trials revealed a reduction in 
ulcer size and ischemic pain, with a decrease in amputation rates [46]. 
Patients with PAD have increased plasma viscosity and erythrocyte 
aggregation, a consequence of hyperfibrinogenemia. This condition can cause 
limitations in blood flow and oxygenation. Low-dose urokinase is a safe, feasible and 
effective therapy that improves microcirculation in diabetic patients with CLI. The most 
recent trial using urokinase in these patients was published in 2008 and supports this 
therapeutic approach [46]. Low molecular weight heparin (dalteparin 5000 U daily) has 
equally demonstrated significant positive effects on skin microcirculation, ulcer 
outcome and hemostasis, when associated with traditional medication/treatment in these 
patients [47, 48]. 
Therapeutic angiogenesis is an investigational approach to the treatment of 
CLI. It consists in the induced formation of a capillary network in ischemic tissues by 
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creating a proangiogenic environment. Two modalities have been studied: gene therapy 
and autologous bone marrow transplantation[49].  
Gene therapy is a rising technique suitable for vascular application, and has 
been the subject of continued testing in many trials. Various angiogenic growth factors, 
such as vascular endothelial cell growth factor (VEGF), fibroblast growth factor (FGF), 
and hepatocyte growth factor (HGF), have been studied, with naked plasma DNA, viral 
genes and liposomal genes serving as vectors. Administration may be intra-muscular or 
intra-arterial, and can be continued over a 4- to 8-week period. Though results vary 
according to the different combination of vector and product, a meta-analysis of existing 
trials has proven the general efficacy of therapeutic angiogenesis in CLI. Mortality rates 
did not present significant differences in comparison to placebo, but there was a higher 
risk for adverse effects such as edema, hypotension and proteinuria in gene therapy [49]. 
Bone marrow is a rich reservoir of tissue-specific stem and progenitor cells. 
Studies show that endothelial progenitor cells play a part in revascularization, being 
mobilized to the injured tissue in response to tissue ischemia and improving collateral 
vessel formation [50]. Bone marrow transplantation can be achieved by intramuscular or 
intra-arterial injection of autologous bone marrow-derived mononuclear cells, and has 
been proved safe and effective in patients with CLI,  accelerating wound healing and 
reducing major amputation rates [51, 52]. Granulocyte-colony stimulating factor which 
induces mobilization of bone marrow cells may be administered subcutaneously before 
transplantation [53]. These exploratory findings require further trials to be confirmed, 
using a greater number of participants and determining if and how this method may be 
of use to diabetics. The population subset to most benefit from this procedure is also yet 
to be defined.  
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Amputation 
Amputations are urgent or curative [54]. Primary amputation should only be 
considered when all other options fail or are unsuitable. Indications for amputation 
include a non-revascularizable lower limb, bed confinement, reduced ambulation that is 
not worsened by amputation and a  life expectancy of less than 1 year [25, 55]. 
Amputation should be as distal and conservative as possible to maintain functionality, 
as the preservation of leg length aids ambulation and decreases energy expenditure. 
Infected or gangrenous tissue should be removed and the surgical site should be allowed 
to heal [25]. When there is large volume tissue necrosis and a functionally unsalvageable 
foot, a need to control sepsis or the presence of non-healing wounds despite patent 
revascularization, amputation below the knee is necessary [55]. 
 
Prognosis 
In neuroischemic legs, healing is primarily affected by the severity of ischemia 
[12]. Most studies report limb salvage rates after revascularization procedures between 
80-85% and ulcer healing in >60% at 12 months [3]. The correct selection of 
revascularization method is key, as early failures often lead to rapid deterioration of the 
limb [56]. Comorbidity significantly increases with the severity of foot disease and is 
strongly related to prognosis [14]. Diabetic foot disease should be considered a life-long 
condition since patients with previous ulcers are always at high risk of developing a 
new ulcer [21].  
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Prevention 
A strategy including regular examination of the feet, inspection and use of 
appropriate footwear, identification of the high-risk patient, education of patient, family 
and health care staff, and treatment of non-ulcerative pathology can increase the 
patient’s   awareness   of   his   problem,   his   ability   for   self-management and reduce the 
number of minor foot lesions. These measures, along with a multidisciplinary treatment 
of ulcers and close monitoring, can reduce amputation rates by 49-85% [6]. 
A study conducted over a period of 20 years assessing the incidence rates of 
amputations indicated a decrease in the incidence of major lower extremity amputations 
(transtibial or higher) by more than half in diabetic patients and an increase in minor 
amputations (amputation below or through the ankle). The low incidence of major 
amputations was maintained over the years, despite the increasing prevalence of 
diabetes and an aging population. These results reflect the benefits of the increasing 
implementation and access to multidisciplinary foot care teams, as well as an increase in 
invasive vascular interventions [57]. 
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Conclusion 
Traditional critical ischemia criteria are not applicable in the diabetic patient. 
CLI is not easily suspected in diabetics due to peripheral neuropathy, as ischemic 
symptoms of the lower limbs may be absent and the first manifestations of PAD 
recognized only when foot ulcers have progressed to the point of gangrene. Also, ABI 
may be falsely elevated because of media calcinosis. Consequently, medical 
investigation and treatment may be delayed on part of both the patient and the health 
care professional. The implementation of a multidisciplinary management strategy with 
a protocol driven approach has proved to be successful in reducing amputation rates. 
When a diabetic patient presents with a foot ulcer, a multifactorial approach and 
aggressive management of underlying CLI and infection is vital. Understanding the 
underlying pathophysiology is also essential in selecting the best treatment options. 
When revascularization is necessary, the choice between an open or endovascular 
intervention  should  be  based  on  the  patient’s  risk  (general  health  status,  comorbidities),  
severity of ischemia, arterial anatomy and conduit availability. Efforts have been made 
to discover noninvasive therapy for patients in whom revascularization is not an option 
or has been unsuccessful. It should be remembered that the diabetic foot is a life-long 
disease, since patients with previous ulcers are permanently at high risk of developing a 
new ulcer.  
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